Adrienne Waks, MD


HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Maria-Victoria Mateos, MD, PhD


Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

Sarah M. Tolaney, MD, MPH


Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.

Fareed Khawaja, MBBS


Oncology On-The-Go Podcast: COVID-19 Vaccination and Cellular Therapy in Cancer

Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.

Neel Talwar, MD


Looking Ahead in the Multiple Myeloma Treatment Landscape

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

Christopher Lieu, MD


MRD and Decision-Making in Early-Stage Colorectal Cancer

This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.

Elizabeth Travers, PharmD, BCOP


Expert Commentary on the Product Profile of Asciminib

In an interview with ONCOLOGY®, Elizabeth Travers, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of asciminib as therapy for patients with chronic myeloid leukemia.

Deni Leonardo Fontes Jardim, MD, PhD


Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic

This article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.

Candice Roth, MSN, RN, CENP


Candice Roth, MSN, RN, CENP, Describes the Evolution of Electronic Treatment Pathways at Levine Cancer Institute

Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.

Thomas E. Hutson, DO, PharmD


Diagnosis and Risk Stratification of Patients With RCC

Dr Thomas Hutson outlines the diagnosis and staging of renal cell carcinoma, the surgical and non-surgical treatment options, and notes that while the majority of cases are potentially curable, 20-25% of patients present with or later develop metastatic disease.

Dhaval Mehta, MD


Quad Therapy and Risk Stratification in Multiple Myeloma

Comprehensive insights on quadruplet therapy regimens and the risk stratification process for patients with multiple myeloma.

Wayne G. Brisbane, MD


AI May Assist in Prostate Cancer Diagnosis, Risk Stratification, and Treatment

Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Courtney Schepel, BS


Integrative Oncology in Young Women With Breast Cancer

Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.

Abigail Mateos-Soria, MD


Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.

Marytere Herrera-Martinez, MD


Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?

A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.

Ira Winer, MD, PhD, FACOG


Ira Winer, MD, PhD, Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian Cancer

Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.

Jules Cohen, MD


Evolving Landscape of HR+ Metastatic Breast Cancer Management

Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.

Viktor Grünwald, MD, PhD


Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCC

CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.